Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Barinthus Biotherapeutics ( (BRNS) ) is now available.
On September 29, 2025, Barinthus Biotherapeutics (Beacon) agreed to a complex cross-border combination under which newly formed Beacon Topco, Inc. would acquire Beacon via a U.K. scheme of arrangement, while Cdog Merger Sub, Inc. would merge with Clywedog Therapeutics, Inc., leaving Clywedog as a wholly owned subsidiary of Topco. On February 22, 2026, the parties amended the merger agreement, revising the Scheme Exchange Ratio to a board-determined range of 0.1 to 0.166667 and the Merger Exchange Ratio to a range of 0.000305 to 0.000508, preserving the agreed post-closing ownership split in Topco.
The February 22, 2026 amendment also expanded minimum cash requirements for both Clywedog and Beacon to cover assumed closing dates of May 31, 2026 and June 30, 2026, respectively, reflecting an unexpected delay in the transaction timeline caused by U.S. federal government shutdowns. These changes signal an effort to stabilize the capital structure and deal economics despite regulatory and timing disruptions, with implications for shareholder ownership, liquidity planning, and the overall execution risk of the cross-border merger.
The most recent analyst rating on (BRNS) stock is a Sell with a $0.71 price target. To see the full list of analyst forecasts on Barinthus Biotherapeutics stock, see the BRNS Stock Forecast page.
Spark’s Take on BRNS Stock
According to Spark, TipRanks’ AI Analyst, BRNS is a Neutral.
The score is driven primarily by weak financial performance (no TTM revenue, large losses, and ongoing cash burn). Technicals add pressure with a below-long-term-average price and negative MACD, while corporate events are mixed—Nasdaq bid-price non-compliance is a major risk despite encouraging early clinical-trial progress.
To see Spark’s full report on BRNS stock, click here.
More about Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, also referred to as Beacon, is a U.K.-incorporated biotherapeutics company focused on developing innovative therapeutic product candidates. The company operates in the life sciences sector and accesses U.S. capital markets through SEC filings, targeting investors interested in emerging biotechnology and therapeutics pipelines.
Average Trading Volume: 67,854
Technical Sentiment Signal: Sell
Current Market Cap: $26.95M
Find detailed analytics on BRNS stock on TipRanks’ Stock Analysis page.